Patients with metastatic cancer who are treated with an anti-programmed death therapy are at an increased risk for neurological complications. READ MORE
Improving provider response to adverse events through an algorithm.
Patients with metastatic cancer who are treated with an anti-programmed death therapy are at an increased risk for neurological complications.
A recent phase III trial demonstrated that initial therapy with an immuno-agent improves PFS in patients with HR+, HER2- breast cancer.
Many patients with stage IV metastatic cancer achieve stable disease after treatment with radiation therapy and immunotherapy.
Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair.
Research in Review
Human epidermal growth factor receptor 2-targeted therapy results in different objective response rates across cancer types based on mutation variants.
A recent clinical trial of a CAR T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive NHL independent of disease type, stage, or characteristics.
A targeting agent is more effective in improving progression-free survival and overall survival than conventional therapy in older patients with a treatment-naïve B-cell malignancy.
Scientists said on Monday they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.